FDA Approves First Treatment for Nonmetastatic CRPC

The US Food and Drug Administration (FDA) has approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer. The oral androgen-receptor inhibitor is the first FDA-approved treatment for patients with nonmetastatic castration-resistant disease and the first to be approved based on the endpoint of metastasis-free survival.

Source: CancerNetwork - February 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Editorial Men ' s Health Prostate Cancer Source Type: news